KLRA vs NVO
KLRA: A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential. NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access.
Side-by-side fundamentals
| Metric | KLRA | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.79 | $48.19 | |
| Market cap as of 2026-07-23 | $2.4B | $219.8B | |
| P/E as of 2026-07-23 | n/a | 11.78 | |
| PEG as of 2026-07-23 | n/a | 16.16 | |
| Net margin as of 2026-07-23 | n/a | +37.2% | |
| Gross margin as of 2026-07-23 | n/a | +81.8% | |
| Operating margin as of 2026-07-23 | n/a | +45.3% | |
| ROE as of 2026-07-23 | -23.4% | +66.4% | NVO higher |
| ROA as of 2026-07-23 | -21.5% | +23.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.72 | KLRA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +8.1% | |
| Dividend yield as of 2026-07-23 | n/a | +3.7% | |
| Beta as of 2026-07-23 | 1.68 | 1.85 | |
| 1-year return as of 2026-07-22 close | -29.2% | -23.8% | NVO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.